Ivermectine effect in treatment and prophylaxis of patients and exposed idividuals with COVID-19

Phase 1

• Conditions: Covid-19 Disease.; Covid-19 Disease; U07.1

• Registration Number: IRCT20200818048444N3
• Lead Sponsor: Ministry of Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 June 2021

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

Patients with diagnosis of COVID-19 disease

Exclusion Criteria

History of allergy to ivermectin, and evidence for current helminthic disease
Advanced renal failure with GFR<30
Advanced liver failure
Advanced malignancy
Severe heart failure or active cardiac arrhythmia

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Patient mortality. Timepoint: Within 28 days after the onset of the disease. Method of measurement: Physician report.;Transfer to ICU. Timepoint: Within 28 days after the onset of the disease. Method of measurement: Physician report.;Intubation or mechanical ventilation. Timepoint: Within 28 days after the onset of the disease. Method of measurement: Physician report.

Secondary Outcome Measures

Name	Time	Method
Improve clinical symptoms. Timepoint: Start treatment up to 28 days. Method of measurement: Physician report.;CRP value. Timepoint: Start treatment up to 28 days. Method of measurement: Measurements in serum.;LDH value. Timepoint: Start treatment up to 28 days. Method of measurement: Measurements in serum.;NLR value. Timepoint: Start treatment up to 28 days. Method of measurement: Measurement with CBCD.